Develop, manufacture, and distribute pharmaceutical drugs for a wide range of medical conditions. Now — the numbers.
This is an established company with proven profits.
An average decline of 4% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $1.1B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 6.4× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 57% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 24% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 4 years, sales fell about 4% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.